Tag: Bayer

Bayer's ambitious corporate overhaul is facing intensified pressure from external uncertainties. As CEO Bill Anderson drives internal cost-cutting initiatives, the ...

The German pharmaceutical and agricultural giant Bayer finds itself at a critical juncture. Its immediate prospects hinge on two pivotal ...

In a notable display of conviction, two senior executives at the German pharmaceutical and life sciences giant Bayer AG recently ...

Bayer's latest financial results present a stark dichotomy. While the company's core business operations demonstrate resilience, its bottom line continues ...

Bayer's recently published annual report for 2025 delivers an unambiguous message: the legal risks associated with glyphosate continue to overshadow ...

Bayer's stock finds itself at a pivotal juncture as investors weigh operational improvements against the company's pharmaceutical pipeline potential. The ...

Bayer shares experienced a decline on Wednesday, despite the company announcing a significant advancement in its Parkinson's disease treatment program. ...

Bayer's subsidiary AskBio has initiated a European Phase II clinical trial for its innovative gene therapy candidate, AB-1005, targeting Parkinson's ...

Bayer AG faces renewed pressure as a highly anticipated cardiovascular drug candidate failed to meet its primary endpoint in critical ...

Bayer's pharmaceutical division has encountered a significant clinical development hurdle as its promising heart failure drug candidate, Vericiguat, failed to ...